title: Sex differences in U50,488H-induced phosphorylation of p44/42 mitogen-activated protein kinase in the guinea pig brain.
abstract: Recently there has been a widespread interest in the development of kappa opioid receptor (KOPR) ligands for treatment of pain, depression and anxiety, and prevention of stress-induced drug relapse. However, most of these preclinical studies have been conducted using male experimental animals. In the present study we examined if sex differences exist in neural activity induced by the KOPR agonist trans-(±)-3,4-dichloro-N-methyl-N-(2-[1-pyrrolidinyl]-cyclohexyl) benzeneacetamide methanesulfonate (U50,488H). Here, we used immunohistochemistry to detect activation (phosphorylation) of p44/42 mitogen-activated protein kinase (MAPK) as an indicator of neural activity. Following habituation to injection for 3 days, adult guinea pigs received a single injection of U50,488H (5mg/kg, s.c.) and perfused 30-45 min later. U50,488H-induced an increase in the number of cells immuno-positive for phosphorylated p44/42 MAPK in subregions of the amygdala, thalamus, paraventricular nucleus of the hypothalamus, periaqueductal gray, and dorsal raphe nuclei. In contrast, U50,488H-induced a decrease in immuno-positive cells in the ventrolateral and lateral orbital cortex. Pretreatment with the KOPR antagonist norbinaltorphimine (10mg/kg, i.p.) 18 h prior to U50,488H significantly reversed the effects of U50,488H in most regions. In addition, we observed a notable sex difference in the basolateral amygdala; in males, U50,488H induced an increase in immuno-positive cell numbers but a decrease in females. However, across other brain regions males were generally more sensitive to U50,488H-induced alterations than females. These results suggest the need to include female subjects in studies examining emotional responses to KOPR ligands.
authors.affiliation: Department of Pharmacology and Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA, United States.
authors.forename: K
authors.initials: K
authors.lastname: Rasakham
authors.forename: K L
authors.initials: KL
authors.lastname: McGillivray
authors.forename: L-Y
authors.initials: LY
authors.lastname: Liu-Chen
mesh_terms: D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer / Q000494:pharmacology*; D018712:Analgesics, Non-Narcotic / Q000494:pharmacology*; D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000201:enzymology; D001931:Brain Mapping; D005260:Female; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D006168:Guinea Pigs; D008297:Male; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism*; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism*; D010766:Phosphorylation / Q000187:drug effects; D012727:Sex Characteristics
chemical_list: D018712:Analgesics, Non-Narcotic; D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3